San Francisco, California — January 12, 2026 — Leads & Copy —
NantWorks, LLC, and ImmunityBio, Inc. (NASDAQ: IBRX) announced the inaugural U.S.-Saudi Biotech Alliance Summit, to be held in conjunction with the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026, from 9:00 a.m. to 5:30 p.m. Pacific Time.
The Summit, convened by NantWorks, will bring together national leaders from the United States and the Kingdom of Saudi Arabia across government, healthcare delivery, biotechnology, advanced manufacturing, artificial intelligence, and finance. It is designed to foster implementation and collaboration to accelerate the development, manufacturing, and global deployment of next-generation immunotherapies and healthcare technologies.
Co-chairs include Her Royal Highness Dr. Haya bint Khaled Al Saud, Senior Vice President of Research at the Hevolution Foundation; His Excellency Dr. Bandar Alknawy, Chief Executive Officer of the Ministry of National Guard Health Affairs and President of King Saud bin Abdulaziz University for Health Sciences; and Dr. Patrick Soon-Shiong, Founder and Executive Chairman of NantWorks and Founder, Executive Chairman, and Global Chief Medical and Scientific Officer of ImmunityBio.
According to Dr. Soon-Shiong, the Summit reflects a shared commitment to translating scientific innovation into real-world patient impact. He stated that by aligning national leadership from the United States and Saudi Arabia, the forum is designed to accelerate implementation, strengthen regulatory and manufacturing pathways, and expand access to breakthrough therapies for cancer and life-threatening infectious diseases. He added that the initiative is about moving from strategy to execution.
The morning program will feature keynote addresses, ministerial presentations, and panel discussions addressing Saudi Arabia’s National Biotechnology Strategy, regional and global biomanufacturing hubs, pandemic and health-security preparedness, regulatory alignment, and U.S.–Saudi investment and commercialization pathways. Afternoon sessions will highlight scientific and technological advances in immunotherapy, antibody discovery, artificial intelligence, robotics, and digital health.
The Summit underscores a broader bilateral effort to strengthen healthcare resilience, modernize AI-driven manufacturing, expand clinical research infrastructure, and enhance long-term preparedness for global health threats, while improving access to advanced therapies across regions.
Additional speakers include senior representatives from the Saudi Ministry of Investment, the Ministry of Health, and the Saudi Food & Drug Authority. Senior representatives from the U.S. administration, committed to national preparedness and the resilience of key infrastructure, will also participate, along with leading U.S. life sciences innovators, investors, and financial institutions.
Presentations from the Summit will be recorded and made available on the ImmunityBio website in the News and Events section. The Summit will also be streamed on the homepage of LATimes.com on Friday, January 16, 2026.
Attendance is by invitation and subject to review. Individuals interested in registering may submit professional credentials and profiles for consideration by emailing RSVP@NANT.com.
ImmunityBio is a vertically integrated commercial stage biotechnology company developing next-generation therapies that bolster the natural immune system to defeat cancers and infectious diseases. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates NK cells, T cells, and memory T cells for a long-duration response.
NantWorks, LLC applies advanced science and technology to address some of the world’s most complex challenges. The company serves as the parent organization to a portfolio of private and public companies operating across three core pillars: Health & Life Sciences, Energy & Renewables, and Connectivity & Communications.
Founded by physician, scientist, and inventor Dr. Patrick Soon-Shiong, NantWorks is focused on the convergence of biology, engineering, computing, and data to accelerate discovery, expand manufacturing capability, and improve healthcare outcomes globally.
Contact: RSVP@NANT.com
Source: ImmunityBio
